Clinical Trial: Compassionate Use Ponatinib

Study Status: No longer available
Recruit Status: No longer available
Study Type: Expanded Access

Official Title: Treatment Plan for the Compassionate Use of Ponatinib (AP24534) in Patients With Imatinib-, Dasatinib-, and Nilotinib- Resistant/Intolerant Philadelphia Chromosome Positiv

Brief Summary: The main purpose of this protocol is to provide expanded access to the study drug (Ponatinib/AP24534) for people with imatinib-, dasatinib-, and nilotinib- resistant/intolerant Philadelphia Chromosome Positive (Ph+) Leukemias. The other purpose of this protocol is to monitor the safety of the study drug in people with Ph+ Leukemias that have not responded to prior treatment.

Detailed Summary:
Sponsor: OHSU Knight Cancer Institute

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: OHSU Knight Cancer Institute

Dates:
Date Received: March 6, 2012
Date Started:
Date Completion:
Last Updated: March 13, 2013
Last Verified: March 2013